New: NCI-funded clinical trial search
Mednet Logo

How do you approach dosing for post-op HNSCC nodal regions with ECE?

Do you modify your dose based on p16 or extent of ECE (e.g. microscopic vs macroscopic)?
4 Answers
Mednet MemberInvited Expert
Radiation Oncology · University of Rochester
Answered on

This is an area in which the communication between surgeon, pathologist, radiologist, and radiation oncologist is particularly helpful. While our surgeons try to submit nodes with descriptive identification of the nodal level they arise from, it still occasionally happens that we see a pathology report that says "2 of 12 level II-IV nodes involved". When we can (with a high degree of certainty) identify the area of ECE we increase the dose to 66 Gy in 33 fractions (or 63 Gy in 30 fractions) while treating the lower risk areas to 60 Gy in 30 fractions. At this time we continue to struggle with how to use HPV status in this setting. In general, if HPV+ with minimal ECE I am more likely to not increase the dose, especially if i can not localize the position of it.

Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on
I think 60 in 2 is enough with chemo.
Mednet MemberInvited Expert
Radiation Oncology · Medical University of South Carolina, Charleston
Answered on

60 Gy for p16 positive

66 Gy for p16 negative

I do not factor in extent of ENE

Mednet Member
Radiation Oncology · University of Missouri at Columbia, Ellis Fischel Cancer Cener
Answered on
A very good question. For high risk areas at least 60Gy (and up to 66 Gy) with chemotherapy which was the experimental arm in the RTOG/EORTC combined series, and most protocols have used that dose range. https://www.ncbi.nlm.nih.gov/pubmed/16161069?dopt=Abstract I have used 64-66 Gy for ENE and 66 Gy for positive margins, because local control for non HPV sites with high risk features (particularly oral cavity) is still a major factor. https://www.ncbi.nlm.nih.gov/pubmed/25376116 For HPV positive OPC, dose de-escalation does not have any high level evidence for high risk features. Washington University published on 60 Gy vs 66 Gy retrospectively for those high risk patients and found no difference with regard to dose. I think this is reasonable, but would require prospective data to confirm this. https://www.ncbi.nlm.nih.gov/pubmed/27152851 Also the extent of ENE is a factor too. Minor extension may not always require higher dose and chemotherapy, but that is another area of uncertainty. I know some institutions are considering lower dose or RT alone for minor ENE. But this needs to proceed with caution and prospective evidence https://www.ncbi.nlm.nih.gov/pubmed/27258054 So in summary, I think post operative RT to doses > 60 Gy for positive margins and ENE is appropriate, with consideration of 60 Gy for HPV OPC cancer with caution for now.